生脉散合加味升陷汤对气虚血瘀型射血分数降低的心力衰竭的疗效观察

doi:10.11958/20251179

天津医药 ›› 2025, Vol. 53 ›› Issue (8): 860-864.doi: 10.11958/20251179

生脉散合加味升陷汤对气虚血瘀型射血分数降低的心力衰竭的疗效观察

李迎杰¹(), 张航¹, 郝少婷¹^,^△(), 许菲¹, 郭魏超¹, 宋惠², 王艳芬³

1 邯郸明仁医院心病二科（邮编056000）
2 唐山市人民医院心内二科
3 邯郸明仁医院心病三科

收稿日期:2025-03-24 修回日期:2025-05-21 出版日期:2025-08-15 发布日期:2025-08-12
通讯作者: ^△E-mail：haoshaoting1987@163.com
作者简介:李迎杰（1981），女，副主任医师，主要从事心脏病、心力衰竭方面研究。E-mail：m15931044949@163.com
基金资助:
河北省中医药管理局科研计划项目(2025616)

Observation on the therapeutic effect of Sheng Mai San mixed Jiawei Sheng Xian Tang on heart failure with reduced ejection fraction of Qi deficiency blood stasis type

LI Yingjie¹(), ZHANG Hang¹, HAO Shaoting¹^,^△(), XU Fei¹, GUO Weichao¹, SONG Hui², WANG Yanfen³

1 Department of Heart Disease 2, Handan Mingren Hospital, Handan 056000, China
2 Department of Cardiology 2, Tangshan People's Hospital
3 Department of Heart Disease 3, Handan Mingren Hospital

Received:2025-03-24 Revised:2025-05-21 Published:2025-08-15 Online:2025-08-12
Contact: ^△E-mail：haoshaoting1987@163.com

李迎杰, 张航, 郝少婷, 许菲, 郭魏超, 宋惠, 王艳芬. 生脉散合加味升陷汤对气虚血瘀型射血分数降低的心力衰竭的疗效观察[J]. 天津医药, 2025, 53(8): 860-864.

LI Yingjie, ZHANG Hang, HAO Shaoting, XU Fei, GUO Weichao, SONG Hui, WANG Yanfen. Observation on the therapeutic effect of Sheng Mai San mixed Jiawei Sheng Xian Tang on heart failure with reduced ejection fraction of Qi deficiency blood stasis type[J]. Tianjin Medical Journal, 2025, 53(8): 860-864.

摘要/Abstract

摘要：

目的探讨生脉散合加味升陷汤对气虚血瘀型射血分数降低的心力衰竭（HFrEF）患者的治疗效果，及对患者免疫炎症反应的影响。方法选取90例气虚血瘀型HFrEF患者，根据治疗方案分为2组，其中常规组（42例）口服沙库巴曲缬沙坦钠片，联合组（48例）在常规组基础上加用生脉散合加味升陷汤，每日1剂，分2次早晚服用。分别在治疗前后采用中医证候积分评估患者症状；超声心动图技术测量患者的左心室舒张末期内径（LVEDD）和左心室射血分数（LVEF）；酶联免疫吸附试验检测正五聚蛋白3（PTX3）、肿瘤坏死因子-α（TNF-α）、半乳糖凝集素3（Gal-3）、白细胞介素（IL）-8、IL-6、IL-33、血管紧张素Ⅱ（AngⅡ）；免疫荧光分析法检测N-末端脑钠肽前体（NT-proBNP）；根据症状和美国纽约心脏病协会（NYHA）心功能分级评估疗效。结果治疗后2组患者的中医证候积分、LVEDD、TNF-α、IL-8、IL-6、IL-33、NT-proBNP、Gal-3、AngⅡ、PTX3水平均降低，且联合组均低于常规组（P<0.05）；LVEF升高，且联合组高于常规组（P<0.05）。治疗后，联合组总有效率高于常规组（P<0.05）。结论生脉散合加味升陷汤辅助治疗能够有效降低气虚血瘀型HFrEF患者体内的免疫炎性细胞因子水平，改善患者的临床症状，提高临床疗效。

关键词: 心力衰竭, 生脉散, 升陷汤, 气虚血瘀, 炎症, 左心室射血分数

Abstract:

Objective To investigate the therapeutic effect of Sheng Mai San mixed Jiawei Sheng Xian Tang on patients with heart failure with reduced ejection fraction (HFrEF) of Qi deficiency blood stasis type, and its impact on the immune inflammatory response of patients. Methods Ninety patients with HFrEF of Qi deficiency blood stasis type were selected and divided into two groups according to the treatment plan. Patients of the conventional group (42 cases) took sacubitril/valsartan sodium tablets orally. Patients of the combined group (48 cases) were treated with Sheng Mai San combined with Jiawei Sheng Xian Tang on the basis of the conventional group, one dose per day, and divided it in two servings used in the morning and evening. The symptoms of the patients were evaluated by using traditional Chinese medicine (TCM) syndrome score before and after the treatment respectively. Echocardiography technology was used to measure the left ventricular end-diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF). Enzyme-linked immunosorbent assay was used to detect pentaggrin 3 (PTX3), tumor necrosis factor -α (TNF-α), galectin-3 (Gal-3), interleukin (IL) -8, IL-6, IL-33 and angiotensin Ⅱ (Ang Ⅱ). N-terminal pro-brain natriuretic peptide (NT-proBNP) was detected by immunofluorescence analysis. The therapeutic effect was evaluated based on the symptoms and the New York Heart Association (NYHA) cardiac function classification in the United States. Results After treatment, the levels of TCM syndrome scores, LVEDD, TNF-α, PTX3, IL-8, IL-6, IL-33, NT-proBNP, Gal-3 and AngⅡ decreased in both groups, and those in the combined group were lower than those in the conventional group (P<0.05). The LVEF increased, and which were higher in the combined group than those of the conventional group (P<0.05). After the treatment, the total effective rate of the combined group was higher than that of the conventional group (P<0.05). Conclusion The Sheng Mai San mixed Jiawei Sheng Xian Tang as adjuvant therapy can effectively reduce the levels of immune inflammatory cytokines in HFrEF patients of Qi deficiency blood stasis type, improve their clinical symptoms and enhance therapeutic effect.

Key words: heart failure, Sheng Mai San, Sheng Xian Tang, Qi deficiency blood stasis, inflammation, left ventricular ejection fraction

中图分类号:

R541.6

图/表 5

参考文献 20

[1]	SAVARESE G, STOLFO D, SINAGRA G, et al. Heart failure with mid-range or mildly reduced ejection fraction[J]. Nat Rev Cardiol, 2022, 19(2):100-116. doi:10.1038/s41569-021-00605-5.
[2]	NIU C Y, YANG S F, OU S M, et al. Sacubitril/Valsartan in patients with heart failure and concomitant end-stage kidney disease[J]. J Am Heart Assoc, 2022, 11(18):e026407. doi:10.1161/JAHA.122.026407.
[3]	赵桂芳, 翟大娟, 谈金强, 等. 活心丸联合沙库巴曲缬沙坦对射血分数降低型慢性心力衰竭患者的临床效果观察[J]. 中外女性健康研究, 2024(4):53-55.
	ZHAO G F, ZHAI D J, TAN J Q, et al. Observation on the clinical effect of huoxin pills combined with sacubitril/valsartan on patients with chronic heart failure with reduced ejection fraction[J]. Women's Health Research, 2024(4):53-55.
[4]	李光智, 林称心, 王转转. 生脉散合血府逐瘀汤加减方对气阴两虚、心血瘀阻型慢性心力衰竭患者相关疗效性指标及NT-proBNP ACR的影响[J]. 广州中医药大学学报, 2023, 40(6):1349-1354.
	LI G Z, LIN C X, WANG Z Z, et al. Effects of modified formula of Shengmai Powder plus Xuefu Zhuyu Decoction on the efficacy indicators and NT-proBNP and albumin-creatinine ratio in patients with chronic heart failure of Qi-Yin deficiency and heart-blood stasis obstruction type[J]. Journal of Guangzhou University of Traditional Chinese Medicine, 2023, 40(6):1349-1354. doi:10.13359/j.cnki.gzxbtcm.2023.06.007.
[5]	田志广. 加味升陷汤辅治慢性心力衰竭临床观察[J]. 实用中医药杂志, 2024, 40(2):254-256.
	TIAN Z G. Clinical observation on the adjuvant treatment of chronic heart failure with modified shengxian decoction[J]. Journal of Practical Traditional Chinese Medicine, 2024, 40(2):254-256.
[6]	中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10):760-789.
	Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association, Chinese Heart Failure Association of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiology. Chinese guidelines for the diagnosis and treatment of heart failure 2018[J]. Chin J Cardiol, 2018, 46(10):760-789. doi:10.3760/cma.j.issn.0253-3758.2018.10.004.
[7]	郑筱萸. 中药新药临床研究指导原则:试行[M]. 北京: 中国医药科技出版社, 2002:77-85.
	ZHENG X Y. Guiding principles for clinical research of new chinese medicines:trial implementation[M]. Beijing: China Medical Science Press, 2002:77-85.
[8]	郭吉雷. 沙库巴曲缬沙坦治疗伴慢性射血分数降低心力衰竭的血液透析患者的效果评价[J]. 中国实用医药, 2024, 19(19):17-20.
	GUO J L. Study on the effect of sacubitril-valsartan in the treatment of hemodialysis patients with chronic heart failure with reduced ejection fraction[J]. China Practical Medical, 2024, 19(19):17-20. doi:10.14163/j.cnki.11-5547/r.2024.19.004.
[9]	张世威, 沈志方, 常国栋. 芪苈强心胶囊辅助沙库巴曲缬沙坦钠治疗射血分数降低型慢性心力衰竭患者的临床疗效[J]. 四川生理科学杂志, 2024, 46(6):1226-1229.
	ZHANG S W, SHEN Z F, CHANG G D. Clinical efficacy of qiliqiangxin capsule supplemented with Sacubitril valsartan sodium in the treatment of patients with chronic heart failure with reduced ejection fraction[J]. Sichuan Journal of Physiological Sciences, 2024, 46(6):1226-1229.
[10]	车驰, 田鑫, 彭双凤, 等. 射血分数降低型心力衰竭中医证型与BNP、CA125表达水平及心功能的相关性分析[J]. 辽宁中医杂志, 2024, 51(2):86-90.
	CHE C, TIAN X, PENG S F, et al. correlation analysis of traditional chinese medicine syndrome types,levels of BNP and CA125 and cardiac function in heart failure with reduced ejection fraction[J]. Liaoning Journal of Traditional Chinese Medicine, 2024, 51(2):86-90. doi:10.13192/j.issn.1000-1719.2024.02.021.
[11]	耿新冉, 杨硕. 生脉散治疗慢性心力衰竭的临床应用现状[J]. 中国临床药理学杂志, 2024, 40(22):3328-3332.
	GENG X R, YANG S. Current status of clinical application of Shengmaisan in the treatment of chronic heart[J]. Chin J Clin Pharmacol, 2024, 40(22):3328-3332. doi:10.13699/j.cnki.1001-6821.2024.22.022.
[12]	李建华, 王明珠, 姚磊, 等. 加味升陷汤联合沙库巴曲缬沙坦钠片治疗慢性射血分数降低的心力衰竭病人的临床疗效观察[J]. 中西医结合心脑血管病杂志, 2022, 20(11):1946-1949,1958.
	LI J H, WANG M Z, YAO L, et al. Clinical observation of Jiawei Shengxian Decoction combined with Entresto in the treatment of chronic heart failure patients with reduced ejection fraction[J]. Chinese Journal of Integrative Medicine on Cardio/Cerebrovascular Disease, 2022, 20(11):1946-1949,1958. doi:10.12102/j.issn.1672-1349.2022.11.004.
[13]	许丁, 赵慧慧, 周淑文, 等. 沙库巴曲缬沙坦与缬沙坦治疗射血分数降低的心力衰竭的临床疗效及其对血清肿瘤坏死因子α、半乳糖凝集素3、基质金属蛋白酶9水平的影响[J]. 实用心脑肺血管病杂志, 2023, 31(1):107-111.
	XU D, ZHAO H H, ZHOU S W, et al. Clinical efficacy of Sacubitril/Valsartan and Valsartan in the teatment of HFrEF and their effect on serum levels of TNF-α,Gal-3,MMP-9[J]. Pract J Cardiac Cereb Pneum Vasc Dis, 2023, 31(1):107-111. doi:10.12114/j.issn.1008-5971.2022.00.188.
[14]	李汶玲, 陈娇娇. 血清前白蛋白和正五聚蛋白3水平对AMI患者PCI术后心力衰竭发生的预测价值[J]. 新疆医科大学学报, 2023, 46(5):643-647.
	LI W L, CHEN J J. Predictive value of serum prealbumin and pentraxin 3 levels for occurrence of heart failure in AMI patients after PCI[J]. Journal of Xinjiang Medical University, 2023, 46(5):643-647. doi:10.3969/j.issn.1009-5551.2023.05.013.
[15]	CHAAR D, DUMONT B, VULESEVIC B, et al. Neutrophils pro-inflammatory and anti-inflammatory cytokine release in patients with heart failure and reduced ejection fraction[J]. ESC Heart Fail, 2021, 8(5):3855-3864. doi:10.1002/ehf2.13539.
[16]	XIANG N, LIAO H, ZHAI Z, et al. Expression and significance of inflammatory reactions mediated by the IL-33/ST2 signaling pathway in the serum of heart failure patients[J]. Am J Transl Res, 2021, 13(7):8247-8252.
[17]	ABUBAKAR M, RASOOL H F, JAVED I, et al. Comparative roles of IL-1,IL-6,IL-10,IL-17,IL-18,1L-22,IL-33,and IL-37 in various cardiovascular diseases with potential insights for targeted immunotherapy[J]. Cureus, 2023, 15(7):e42494. doi:10.7759/cureus.42494.
[18]	张学飞, 张甜田. miR-146a、Gal-3在射血分数保留型心力衰竭患者中的表达及与心室重构的相关性分析[J]. 医学理论与实践, 2024, 37(7):1187-1189.
	ZHANG X F, ZHANG T T. Expression of miR-146a and Gal-3 in patients with heart failure with preserved ejection fraction and correlation analysis with ventricular remodeling[J]. J Med Theor ＆ Prac, 2024, 37(7):1187-1189. doi:10.19381/j.issn.1001-7585.2024.07.039.
[19]	吴政燮, 韩才均, 崔海霞, 等. IL-6、CRP、NLR和NT-proBNP对老年心力衰竭合并肺炎的诊断价值[J]. 检验医学与临床, 2024, 21(9):1250-1253,1258.
	WU Z X, HAN C J, CUI H X, et al. Expression and diagnostic value of IL-6,CRP,NLR and NT-proBNP in elderly patients with heart failure complicated by pneumonia[J]. Lab Med Clin, 2024, 21(9):1250-1253,1258. doi:10.3969/j.issn.1672g9455.2024.09.013.
[20]	何文凤, 薛成, 郑健康, 等. 参松养心胶囊联合沙库巴曲缬沙坦治疗阵发性心房颤动合并慢性心力衰竭对hs-CRP、BNP、AngⅡ及心功能的影响[J]. 中华中医药学刊, 2024, 42(6):95-98.
	HE W F, XUE C, ZHENG J K, et al. Effects of Shensong Yangxin Capsule combined with Sacubatro Valsartan on hs-CRP,BNP,Ang Ⅱ and cardiac function in treatment of paroxysmal atrial fibrillation complicated with chronic heart failure[J]. Chinese Archives of Traditional Chinese Medicine, 2024, 42(6):95-98. doi:10.13193/j.issn.1673-7717.2024.06.018.

组别	n	性别（男/女）	年龄/岁	NYHA心功能分级（Ⅱ/Ⅲ/Ⅳ）
常规组	42	22/20	64.99±9.28	17/20/5
联合组	48	23/25	64.51±9.75	19/21/8
χ²或t		0.179	0.238	0.430

组别	n	性别（男/女）	年龄/岁	NYHA心功能分级（Ⅱ/Ⅲ/Ⅳ）
常规组	42	22/20	64.99±9.28	17/20/5
联合组	48	23/25	64.51±9.75	19/21/8
χ²或t		0.179	0.238	0.430

组别	n		呼吸困难						疲劳无力
组别	n		治疗前		治疗后		t		治疗前		治疗后		t
常规组	42		4.88±0.96		2.08±0.59		16.104^＊＊		5.01±0.79		2.52±0.74		14.908^＊＊
联合组	48		4.92±1.06		1.55±0.41		20.543^＊＊		5.06±0.81		2.09±0.66		19.694^＊＊
t			0.187		4.997^＊＊				0.296		2.914^＊
组别		咳嗽						身体肿胀
组别		治疗前		治疗后		t		治疗前		治疗后		t
常规组		3.69±1.08		2.28±0.61		7.367^＊＊		3.20±0.78		2.03±0.56		7.897^＊＊
联合组		3.77±1.12		1.95±0.63		9.812^＊＊		3.24±0.74		1.78±0.52		11.184^＊＊
t		0.344		2.516^＊				0.249		2.195^＊

组别	n		呼吸困难						疲劳无力
组别	n		治疗前		治疗后		t		治疗前		治疗后		t
常规组	42		4.88±0.96		2.08±0.59		16.104^＊＊		5.01±0.79		2.52±0.74		14.908^＊＊
联合组	48		4.92±1.06		1.55±0.41		20.543^＊＊		5.06±0.81		2.09±0.66		19.694^＊＊
t			0.187		4.997^＊＊				0.296		2.914^＊
组别		咳嗽						身体肿胀
组别		治疗前		治疗后		t		治疗前		治疗后		t
常规组		3.69±1.08		2.28±0.61		7.367^＊＊		3.20±0.78		2.03±0.56		7.897^＊＊
联合组		3.77±1.12		1.95±0.63		9.812^＊＊		3.24±0.74		1.78±0.52		11.184^＊＊
t		0.344		2.516^＊				0.249		2.195^＊

组别	n	LVEF/%			LVEDD/mm
组别	n	治疗前	治疗后	t	治疗前	治疗后	t
常规组	42	31.16±7.38	44.20±10.43	3.571^＊	63.14±14.07	56.42±11.64	2.385^＊
联合组	48	31.04±7.25	49.88±10.95	6.336^＊＊	63.36±14.21	50.87±11.31	4.765^＊＊
t		0.078	2.519^＊		0.074	2.291^＊

生脉散合加味升陷汤对气虚血瘀型射血分数降低的心力衰竭的疗效观察

Observation on the therapeutic effect of Sheng Mai San mixed Jiawei Sheng Xian Tang on heart failure with reduced ejection fraction of Qi deficiency blood stasis type

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 5

参考文献 20

相关文章 15

编辑推荐

Metrics

本文评价

组别	n	显效	有效	无效	总有效
常规组	42	19（45.24）	12（28.57）	11（26.19）	31（73.81）
联合组	48	26（54.17）	18（37.50）	4（8.33）	44（91.67）
χ²					5.143^＊

[1]	于晓猛, 索睿, 杜昕桃, 索莹, 阿亚拉·阿斯哈尔, 郝天旭, 赵晓赟. 人脐带来源的间充质干细胞对慢性间歇低氧小鼠的影响[J]. 天津医药, 2025, 53(8): 814-819.
[2]	陈慧, 赵凯, 刘振国, 常瑛, 巨康璐. 金丝桃素通过调控NLRP3炎症小体改善小鼠急性胰腺炎的机制探讨[J]. 天津医药, 2025, 53(8): 820-825.
[3]	李诚诚, 李龙骧, 于立恒. 灯盏细辛注射液联合阿托伐他汀钙治疗急性缺血性脑卒中的疗效观察[J]. 天津医药, 2025, 53(8): 865-869.
[4]	陈英, 郭长英, 张静, 李娟, 陈丰毅. 基于术前肺动脉压评估心脏移植术后右心衰竭的发生风险[J]. 天津医药, 2025, 53(7): 751-755.
[5]	董玉婷, 龚雪莲, 屈超. 慢性心力衰竭患者血浆IGFBP2、SMOC2水平与心功能及预后的关系[J]. 天津医药, 2025, 53(6): 593-598.
[6]	丁杨娟, 夏时海, 许威, 高庆红, 刘涛涛. 氧化应激及抗氧化剂在急性胰腺炎中的研究进展[J]. 天津医药, 2025, 53(4): 444-448.
[7]	张晶晶, 肖丽丽, 张鑫杰. 复方苦参注射液联合芬太尼透皮贴治疗癌性疼痛的疗效观察[J]. 天津医药, 2025, 53(3): 317-320.
[8]	魏婵娟, 夏晓爽, 冯文军, 李新. 中性粒细胞与淋巴细胞比值对急性缺血性脑卒中患者静脉溶栓预后不良的预测价值[J]. 天津医药, 2025, 53(2): 135-140.
[9]	张小庆, 赵慧霞, 曹鄂洪, 张连霞, 宫秀娟. PIV、HCAR、PCT/PLT在老年COPD肺部感染中的应用价值[J]. 天津医药, 2025, 53(2): 170-175.
[10]	刘鸿雁, 李雅晨, 盛格格, 朱海丽, 吴基良. 紫花前胡苷缓解神经病理性疼痛的机制探讨[J]. 天津医药, 2025, 53(1): 35-41.
[11]	蒋晓涵, 曹杰, 刘丹丹, 薛丹, 郭志国. aMAP评分联合RAR及PIV构建慢性肝病患者肝细胞癌发生风险的预测模型[J]. 天津医药, 2025, 53(1): 42-46.
[12]	刘欢, 张琦, 闫启鹍, 曹路. 首次医疗接触QRS时限与急性ST段抬高型心肌梗死临床终点关系的单中心研究[J]. 天津医药, 2025, 53(1): 71-74.
[13]	魏思澄, 于岁, 于瑛, 李华峰, 张琪, 唐与晓, 王秋灵, 于晓. 2型糖尿病男性患者系统性炎症指标与骨密度的关系[J]. 天津医药, 2025, 53(1): 88-92.
[14]	陈晶晶, 农章嵩, 谭良源, 杨培培, 梁英业, 唐宏亮, 王开龙. 小胶质细胞极化在神经病理性疼痛中作用研究进展[J]. 天津医药, 2024, 52(9): 1000-1003.
[15]	范慧慧, 任玉梅, 田新磊, 张凯, 李晓丽. 止咳平喘方对支气管哮喘小鼠气道炎症及TLR4/TRAF6/NF-κB通路的影响[J]. 天津医药, 2024, 52(9): 924-929.

组别	n			TNF-α/（ng/L）												IL-8/（ng/L）
组别	n			治疗前				治疗后				t				治疗前				治疗后				t
常规组	42			74.89±14.28				59.92±12.79				5.061^＊＊				61.03±11.92				54.81±10.36				2.552^＊
联合组	48			75.11±14.47				54.34±11.46				7.796^＊＊				62.37±12.45				49.73±9.78				5.531^＊＊
t				0.072				2.183^＊								0.520				2.391^＊
组别			IL-6/（ng/L）										IL-33/（ng/L）
组别			治疗前		治疗后				t				治疗前				治疗后				t
常规组			41.15±9.77		33.92±9.13				3.504^＊				123.15±18.43				78.64±13.29				12.695^＊＊
联合组			41.08±9.63		28.81±8.56				6.598^＊＊				122.85±18.24				67.45±12.58				17.322^＊＊
t			0.036		2.739^＊								0.077				4.101^＊＊
组别			NT-proBNP/（ng/L）												Gal-3/（μg/L）
组别			治疗前				治疗后				t				治疗前				治疗后				t
常规组			3 411.03±733.11				2 127.24±491.68				9.425^＊＊				3.54±1.01				2.48±0.75				5.461^＊＊
联合组			3 401.68±735.29				1 647.36±427.45				14.291^＊＊				3.61±1.08				1.93±0.61				9.384^＊＊
t			0.060				4.954^＊＊								0.316				3.835^＊＊
组别		AngⅡ/（ng/L）												PTX3/（ng/L）
组别		治疗前				治疗后				t				治疗前				治疗后				t
常规组		126.71±22.43				111.07±18.23				3.507^＊				161.12±23.37				91.59±17.82				15.333^＊＊
联合组		127.18±22.39				98.46±17.56				6.993^＊＊				160.35±24.92				79.69±16.56				18.677^＊＊
t		0.099				3.339^＊								0.152				3.282^＊

组别	n			TNF-α/（ng/L）												IL-8/（ng/L）
组别	n			治疗前				治疗后				t				治疗前				治疗后				t
常规组	42			74.89±14.28				59.92±12.79				5.061^＊＊				61.03±11.92				54.81±10.36				2.552^＊
联合组	48			75.11±14.47				54.34±11.46				7.796^＊＊				62.37±12.45				49.73±9.78				5.531^＊＊
t				0.072				2.183^＊								0.520				2.391^＊
组别			IL-6/（ng/L）										IL-33/（ng/L）
组别			治疗前		治疗后				t				治疗前				治疗后				t
常规组			41.15±9.77		33.92±9.13				3.504^＊				123.15±18.43				78.64±13.29				12.695^＊＊
联合组			41.08±9.63		28.81±8.56				6.598^＊＊				122.85±18.24				67.45±12.58				17.322^＊＊
t			0.036		2.739^＊								0.077				4.101^＊＊
组别			NT-proBNP/（ng/L）												Gal-3/（μg/L）
组别			治疗前				治疗后				t				治疗前				治疗后				t
常规组			3 411.03±733.11				2 127.24±491.68				9.425^＊＊				3.54±1.01				2.48±0.75				5.461^＊＊
联合组			3 401.68±735.29				1 647.36±427.45				14.291^＊＊				3.61±1.08				1.93±0.61				9.384^＊＊
t			0.060				4.954^＊＊								0.316				3.835^＊＊
组别		AngⅡ/（ng/L）												PTX3/（ng/L）
组别		治疗前				治疗后				t				治疗前				治疗后				t
常规组		126.71±22.43				111.07±18.23				3.507^＊				161.12±23.37				91.59±17.82				15.333^＊＊
联合组		127.18±22.39				98.46±17.56				6.993^＊＊				160.35±24.92				79.69±16.56				18.677^＊＊
t		0.099				3.339^＊								0.152				3.282^＊